Souhaitez-vous accéder aux communiqués récents ?

MINNEAPOLIS, MINNESOTA--(Marketwired - Dec. 20, 2013) - DiaMedica Inc. (TSX VENTURE:DMA), a biotechnology company focused on diabetes, is pleased to announce that at the Annual General...

MINNEAPOLIS, MINNESOTA--(Marketwired - Dec. 16, 2013) - /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ DiaMedica Inc....

MINNEAPOLIS, MINNESOTA--(Marketwired - Dec. 4, 2013) - DiaMedica Inc. (TSX VENTURE:DMA), announced today that it has filed a preliminary short form prospectus in connection with the...

MINNEAPOLIS, MINNESOTA--(Marketwired - Nov. 20, 2013) - DiaMedica (TSX VENTURE:DMA), a clinical stage biopharmaceutical company, has been invited to present at the 25th Annual Piper...

MINNEAPOLIS, MINNESOTA--(Marketwired - Nov. 11, 2013) - DiaMedica Inc. (TSX VENTURE:DMA), announces that the Board of Directors has granted options to purchase 100,000 common shares of...

MINNEAPOLIS, MINNESOTA--(Marketwired - Oct. 30, 2013) - DiaMedica (TSX VENTURE:DMA), a clinical stage biopharmaceutical company is pleased to announce Elsevier Business Intelligence has...

MINNEAPOLIS, MINNESOTA--(Marketwired - Sept. 30, 2013) - DiaMedica (TSX VENTURE:DMA), a clinical stage biopharmaceutical company announced positive results from the second portion of the...

MINNEAPOLIS, MINNESOTA--(Marketwired - Aug. 20, 2013) - DiaMedica (TSX VENTURE:DMA), a clinical stage biopharmaceutical company, today announced that the final Type 2 diabetic patient has...

MINNEAPOLIS, MINNESOTA--(Marketwired - June 26, 2013) - DiaMedica Inc. (TSX VENTURE:DMA), announces that the Board of Directors has granted options to purchase 525,000 common shares of...

MINNEAPOLIS, MINNESOTA--(Marketwired - June 24, 2013) - DiaMedica (TSX VENTURE:DMA), a clinical stage biopharmaceutical company, today provided an update on the ongoing clinical trial...